Phase I Study of Tasquinimod Alone and in | Clinical Research Studies Listing

$Phase I Study of Tasquinimod Alone and in Combination with Standard Therapy for Relapsed or Refractory Myeloma$

Enrolling By Invitation

99 years and younger

All

Phase 1

54 participants needed

1 Location

Brief description of study

The research study is being conducted to understand the effects of tasquinimod, an experimental medication, on patients with myeloma. Eligibile subject have multiple myeloma that has been previously treated and is now in need of additional treatment. Part 1 of this study evaluates tasquinimod alone. Part 2 of this study evaluates tasquinimod in combination with a standard myeloma treatment regimen known as IRd (including ixazomib, lenalidomide, and dexamethasone).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Relapsed,Refractory,Myeloma
Age: - 99 Years
Gender: All

Updated on 01 Aug 2024. Study ID: 842603

If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com